Navigation Links
Ovarian cancer screening not catching early disease
Date:4/1/2009

BIRMINGHAM, Ala. The only available screening tests for ovarian cancer fail to catch early signs of the disease and often result in unnecessary surgery, said researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.

The new study looked at a screening regimen that combines ultrasound and a blood test for CA-125, a marker for women's cancer.

Results showed the combo screening caught 70 percent of the ovarian cancers in their late stages, when effective treatment options are limited.

Knowing this screening limitation means the search has intensified for a better way to detect ovarian cancer, often called the "silent killer," said Edward Partridge, M.D., director of the UAB Comprehensive Cancer Center and the lead study author.

"We still have some comparison data to review, but right now it looks like the positive predictive value of these tests is pretty low," Partridge said.

The study puts the positive predictive value for both tests at around 1.6 percent per 100 positive screening results, a remarkably low positivity rate that led to many false positives, he said. False positives are erroneous signals of cancer where there is none.

The UAB results are published April 1 in the journal Obstetrics & Genecology.

One alarming trend noted in the study is how often transvaginal ultrasound led to a high rate of unnecessary removal of the ovaries, which means no cancer was detected in these organs post-surgery.

"This data suggests that we need a better screening tool. We need a test that is more sensitive and more specific so we find the cancer earlier and we catch the biological markers that give us stronger clues," Partridge said.

The study was part of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO trial) and included more than 72,000 women aged 55 to 74.

The PLCO results coincide with a British study published March 10 online in The Lancet Oncology that found combo screening for ovarian cancer was extremely successful in finding early stage cancers. But that still doesn't mean the screens led to a reduction in the ovarian cancer death rate, reported the British study authors from the University College London.

Ovarian cancer ranks as the fifth leading cause of female cancer death, and it is diagnosed primarily in women aged 55 and older. Early stages of the cancer cause somewhat vague symptoms and many malignancies go undetected until other organs and tissues are involved.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
2. Catching Ovarian Cancer Early May Miss Aggressive Tumors
3. Ovarian cancers detected early may be less aggressive, questioning effectiveness of screening
4. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
5. Combo Screening Doesnt Spot Early Ovarian Cancer
6. Early Detection Remains Key in Updated NCCN Guidelines for Ovarian Cancer
7. Combo of Tests Might Spot Ovarian Cancer Early
8. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
9. Fertility Drugs Do Not Increase Ovarian Cancer Risk
10. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
11. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: